Oculis has gained exclusive global rights to neuroprotective drug candidate for glaucoma through a licensing agreement with Accure Therapeutics.

Moderna has announced that it has entered a Memorandum of Understanding with the government of the Republic of Kenya to establish its first mRNA manufacturing facility in Africa.

What if we are underestimating China’s response to US/EU inshoring?

Researchers at McGill University have made advancements with a novel method for growing synthetic bone tissue.

Bio-Rad has launched a range of antibodies specifically for daratumumab that inhibit the binding of the drug to the target antigen, CD38, which allows for highly specific bioanalysis and drug monitoring.

FDA’s CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development.

The Luna Probe One-Step RT-qPCR Mix with UDG is designed to enable sensitive, linear, real-time detection of target RNA sequences.

Genoox will use their genomic data platform to validate Element's AVITI system.

EMA’s PRIME scheme has enabled life-changing medicines to become available to patients at a faster rate.

Evonik has increased its global supply of plant-derived cholesterol used for mRNA vaccines and gene therapies.

A consortium of nine development partners will support Biovac's expansion of its existing vaccine manufacturing plant capacity, while Biovac itself aims to raise funds to boost increased vaccine manufacturing capacity across Africa.

Aceto has acquired Biotron Laboratories and Talus Mineral Company.

TFF Pharmaceuticals and Catalent will collaborate to develop TFF's platform for manufacturing dry powder particles.

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

In a goal to boost local pharmaceutical production, the World Health Organization has established a global manufacturing training hub in the Republic of Korea through which Bangladesh, Indonesia, Pakistan, Serbia, and Vietnam will receive mRNA technology.

Under a collaboration, IDT Biologika and Exothera will conduct feasibility studies on scaling up the manufacturing process for viral vector-based vaccines.

Continuous improvements in technologies and services will help cold chain operators meet future industry demand.

Pfizer has received Breakthrough Therapy Designation from FDA for its RSV vaccine candidate for prevention of RSV illness in infants by active immunization of pregnant women.

As Russia’s invasion of Ukraine continues, industry leaders speak out in condemnation of the actions taking place and pledge to provide aid to those in need.

FDA has approved Vonjo (pacritinib) capsules to treat adults with a rare form of bone marrow disorder.

Adagene has announced SAFEbody multi-target collaboration with Sanofi for novel masked immuno-oncology antibody candidates.

AbbVie has acquired Syndesi Therapeutics, expanding AbbVie’s neuroscience portfolio.

The UK’s National AI Strategy underpins the government’s long-term commitment and ambitions to enhancing the country’s digital ecosystem, with the health and life sciences sectors seen as pivotal contributors to meeting these aims.

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

Califf will face challenges that include COVID-19, opioids, and user fees.

Borrowing is good, but invention is best.

Reducing US dependency on overseas pharma manufacturing may prove critical in navigating supply chain disruptions.

Although the bio/pharma supply chain has vulnerabilities that still need to be addressed, the COVID-19 pandemic has left lasting effects—some of them for the better.